http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105820163-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate | 2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105820163-B |
| titleOfInvention | The miscellaneous azole compounds of substituted 1,3-, preparation method, pharmaceutical composition and purposes comprising it |
| abstract | The miscellaneous azole compounds of substituted 1,3-, preparation method, pharmaceutical composition and purposes comprising it.The present invention relates to the compound of Formulas I or its pharmaceutically acceptable salt, stereoisomer or solvate, wherein R 1 、R 2 、R 3 It is as defined herein with X；Preparation method, the medical composition and its use comprising it.The compound of the present invention is a kind of Antitubercular compound, it is not only effective to tubercle bacillus sensitive strain, but also for having the antibody-resistant bacterium of drug resistance effective traditional line antituberculotic such as isoniazid and rifampin, and mycobacterium tuberculosis is had good selectivity. |
| priorityDate | 2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 350.